{"groups":[{"description":"DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.","id":"FG000","title":"DN24-02"},{"description":"Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin-containing chemotherapy is beneficial in the adjuvant setting for this patient population.","id":"FG001","title":"Standard of Care"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"30"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"37"}],"type":"Study Terminated"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Site closed research department"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"72"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Safety population for the DN24-02 arm.","type":"DN24-02 Arm ≥1 Leukapheresis"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"72"}],"comment":"Safety population for the Standard of Care arm.","type":"Standard Care Arm ≥1 Post-baseline Visit"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"72"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}